New semaglutide and cagrilintide semaglutide results possibilities in obesity and diabetes care Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Novo Nordisk defends disappointing next gen obesity drug: 'It will be an important product' NBC Connecticut Novo Nordisk's next gen obesity drug CagriSema trial results disappoint investors Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Novo Nordisk: A long acting, selective human insulin analog, NN1213, for weight management